Most incretin-based therapies drive impressive fat loss, but at a cost: significant lean mass depletion worse metabolic health higher long-term risk, especially in Diabetes This graphic highlights a two-pronged approach: Semaglutide reduces appetite & fat mass Bimagrumab blocks ActRIIA/B signalling, preventing muscle atrophy Clinical data (BELIEVE trial) shows that combining the two: enhances fat loss preserves or increases lean mass improves overall body composition, not just the number on the scale In a season where weight gain is almost guaranteed, the future of obesity treatment isnt eat less and lose everything. Its lose fat while building muscle
Her thoughts slowed
Treat it as a clinical question rather than a judgment call that same conversation should also cover whether an interrupted or missed dose affects your plan, which is a decision for your provider
554.50 There are no reviews yet
Obesity is a chronic disease, and we need to treat it like one, says Sara Velayati, MD, an obesity medicine specialist at the Fleischer Institute Medical Weight Management Center at Montefiore Einstein in the Bronx, New York
The combination of both medications modifies your bodys physiology to reduce food intake
